Merck KGaA drops $1.3B in cash on UK gene-silencing biotech
The all-cash deal adds divesiran, a late-stage-ready rare-disease therapy, to Merck KGaA's pipeline and signals a new wave of RNA therapeutics M&A.
By Abdullah Al-Otaibi·· 4 min
Loading the Newsroom
Curating from trusted global sources…